French Innovative Leukemia Organisation
Clinical trials sponsored by French Innovative Leukemia Organisation, explained in plain language.
-
New drug duo tested in fight against rare, aggressive blood cancer
Disease control Not yet recruitingThis study is testing whether combining two drugs, tagraxofusp and venetoclax, is safe and effective for adults newly diagnosed with a rare and aggressive blood cancer called BPDCN. The main goal is to see if this combination leads to a complete remission after three months of tr…
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New oral combo aims to keep devastating blood cancer at bay
Disease control Not yet recruitingThis study is testing whether taking two oral medications, ivosidenib and azacitidine, can help keep a specific type of acute myeloid leukemia (AML) from coming back in older adults. It is for patients aged 55+ who have achieved remission after intensive chemotherapy and have a s…
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New drug duo aims to control tough blood cancer
Disease control Not yet recruitingThis study is testing a combination of two oral drugs, zanubrutinib and BGB-11417, for adults whose Waldenström macroglobulinemia (a rare blood cancer) has come back or stopped responding to prior treatment. The goal is to see if this time-limited, 20-cycle treatment can achieve …
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC